% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{deJager:300187,
author = {V. D. de Jager and P. Giacomini and J. A. Fairley and R. A.
Toledo and S. J. Patton and S. A. Joosse and C. Koch and Z.
C. Deans and K. Pantel and E. Heitzer and E. Schuuring},
collaboration = {E. c. W. Group},
othercontributors = {S. Agelaki and C. L. Andersen and D. Andersson and B.
Bellosillo and I. R. Bergheim and D. van den Broek and Z. C.
Deans and E. Dequeker and J. A. Fairley and B. García
Peláez and P. Giacomini and A. Greystoke and A. Hallermayr
and E. Heitzer and T. J. N. Hiltermann and M. Hubank and S.
Indraccolo and V. D. de Jager and S. A. Joosse and L. Keller
and M. Krebs and M. Ligtenberg and L. Lo Cascio and M. A.
Molina-Vila and K. Nahlik and M. Neumaier and B. Nowack and
A. Oniscu and S. Ossowski and A. Oszwald and N. Pallisgaard
and K. Pantel and S. J. Patton and M. H. Rasmussen and E.
Rouleau and A. Roshan and M. Rot and H. Schlecht and E.
Schuuring and U. Schüller and L. Silwal-Pandit and H.
Sültmann$^*$ and P. Taniere and R. Toledo and N.
Wuerdemann},
title = {{R}eporting of molecular test results from cell-free {DNA}
analyses: expert consensus recommendations from the 2023
{E}uropean {L}iquid {B}iopsy {S}ociety ct{DNA} {W}orkshop.},
journal = {EBioMedicine},
volume = {114},
issn = {2352-3964},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-00664},
pages = {105636},
year = {2025},
abstract = {The implementation of circulating tumor DNA (ctDNA) in the
diagnostic routine may enable non-invasive predictive
biomarker testing and treatment optimization in patients who
lack a suitable tumor specimen, have failed previous
molecular analysis or are clinically ineligible for
(re-)biopsy procedures. As the interpretation and reporting
are more complex for ctDNA than conventional tissue-based
NGS, there is a need for specific guidelines. These will
offer support for the reporting of ctDNA test results and
will facilitate optimal communication of liquid biopsy
findings between diagnostic laboratories and the medical
oncology team. Aiming to generate guidelines based on
real-world experiences and broad perspectives, we organized
a European Liquid Biopsy Society (ELBS) ctDNA workshop, in
which forty-four experts and key stakeholders from different
molecular diagnostics laboratories, oncology and pathology
departments, as well as an IVDR specialist, convened to
address significant challenges associated with the reporting
of liquid biopsy test results. This report delineates the
resulting consensus recommendations for ctDNA test reporting
with underlying rationale and background information.},
subtyp = {Review Article},
keywords = {Expert consensus recommendations (Other) / Liquid biopsy
(Other) / ctDNA test reporting (Other)},
cin = {B063 / HD01},
ddc = {610},
cid = {I:(DE-He78)B063-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40121940},
doi = {10.1016/j.ebiom.2025.105636},
url = {https://inrepo02.dkfz.de/record/300187},
}